While elevated m6A levels are generally considered oncogenic, the m6A eraser FTO has emerged as a promising therapeutic target in certain AML subtypes and, notably, in acquired TKI resistance in both AML and CML [44]. Here, FTO is linked to chronic myelogenous leukemia, BCR-ABL1 positive.